Literature DB >> 24610309

Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: a population-based study.

Harindra C Wijeysundera1, Maria C Bennell, Feng Qiu, Dennis T Ko, Jack V Tu, Duminda N Wijeysundera, Peter C Austin.   

Abstract

BACKGROUND: Randomized studies have shown optimal medical therapy to be as efficacious as revascularization in stable ischemic heart disease (IHD). It is not known if these efficacy results are reflected by real-world effectiveness.
OBJECTIVE: To evaluate the comparative effectiveness of routine medical therapy versus revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in stable IHD.
DESIGN: Observational cohort study. PATIENTS: Stable IHD patients from 1 October 2008 to 30 September 2011, identified using a Registry of all angiography patients in Ontario, Canada. INTERVENTION: Revascularization, defined as PCI/CABG within 90 days after index angiography. MAIN MEASURES: Death, myocardial infarction (MI) or repeat PCI/CABG. Revascularization was compared to medical therapy using a) multivariable Cox-proportional hazard models with therapy strategy treated as a time-varying covariate; and b) a propensity score matched analysis. Post-angiography medication use was determined. KEY
RESULTS: We identified 39,131 stable IHD patients, of whom 15,139 were treated medically, and 23,992 were revascularized (PCI = 15,604; CABG = 8,388). Mean follow-up was 2.5 years. Revascularization was associated with fewer deaths (HR 0.76; 95 % CI 0.68-0.84; p < 0.001) ,MIs (HR 0.78; 95 % CI 0.72-0.85; p < 0.001) and repeat PCI/CABG (HR 0.59; 95 % CI 0.50-0.70; p < 0.001) than medical therapy. In the propensity-matched analysis of 12,362 well-matched pairs of revascularized and medical therapy patients, fewer deaths (8.6 % vs 12.7 %; HR 0.75; 95 % CI 0.69-0.81; p < 0.001) , MIs (11.7 % vs 14.4 %; HR 0.84; 95 % CI 0.77-0.93 p < 0.001) and repeat PCI/CABG ( 17.4 % vs 24.1 %;HR 0.67; 95 % 0.63-0.71; p < 0.001) occurred in revascularized patients, over the 4.1 years of follow-up. The revascularization patients had higher uptake of clopidogrel (70.3 % vs 27.2 %; p < 0.001), β-blockers (78.2 % vs 76.7 %; p = 0.010), and statins (94.7 % vs 91.5 %, p < 0.001) in the 1-year post-angiogram.
CONCLUSIONS: Stable IHD patients treated with revascularization had improved risk-adjusted outcomes in clinical practice, potentially due to under-treatment of medical therapy patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24610309      PMCID: PMC4061359          DOI: 10.1007/s11606-014-2813-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  22 in total

1.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.

Authors:  Adrian R Levy; Bernie J O'Brien; Connie Sellors; Paul Grootendorst; Donald Willison
Journal:  Can J Clin Pharmacol       Date:  2003

Review 2.  Controversies in stable coronary artery disease.

Authors:  Lionel H Opie; Patrick J Commerford; Bernard J Gersh
Journal:  Lancet       Date:  2006-01-07       Impact factor: 79.321

3.  Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York.

Authors:  Edward L Hannan; Zaza Samadashvili; Kimberly Cozzens; Gary Walford; Alice K Jacobs; David R Holmes; Nicholas J Stamato; Jeffrey P Gold; Samin Sharma; Ferdinand J Venditti; Tia Powell; Spencer B King
Journal:  Circulation       Date:  2012-03-22       Impact factor: 29.690

4.  Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality.

Authors:  Harindra C Wijeysundera; Nicholas Mitsakakis; William Witteman; Mike Paulden; Gabrielle van der Velde; Jack V Tu; Douglas S Lee; Shaun G Goodman; Robert Petrella; Martin O'Flaherty; Simon Capewell; Murray Krahn
Journal:  Can J Cardiol       Date:  2011-09-14       Impact factor: 5.223

5.  Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Authors:  William B Borden; Rita F Redberg; Alvin I Mushlin; David Dai; Lisa A Kaltenbach; John A Spertus
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

6.  Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005.

Authors:  Harindra C Wijeysundera; Márcio Machado; Farah Farahati; Xuesong Wang; William Witteman; Gabrielle van der Velde; Jack V Tu; Douglas S Lee; Shaun G Goodman; Robert Petrella; Martin O'Flaherty; Murray Krahn; Simon Capewell
Journal:  JAMA       Date:  2010-05-12       Impact factor: 56.272

7.  Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).

Authors:  Benjamin A Steinberg; P Gabriel Steg; Deepak L Bhatt; Gregg C Fonarow; Uwe Zeymer; Christopher P Cannon
Journal:  Am J Cardiol       Date:  2007-03-16       Impact factor: 2.778

Review 8.  Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis.

Authors:  Thomas A Trikalinos; Alawi A Alsheikh-Ali; Athina Tatsioni; Brahmajee K Nallamothu; David M Kent
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

9.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

10.  Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2011-02-21       Impact factor: 2.373

View more
  5 in total

1.  Relation between initial treatment strategy in stable coronary artery disease and 1-year costs in Ontario: a population-based cohort study.

Authors:  Jaskaran S Kang; Maria C Bennell; Feng Qiu; Merril L Knudtson; Peter C Austin; Dennis T Ko; Harindra C Wijeysundera
Journal:  CMAJ Open       Date:  2016-08-08

Review 2.  Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Authors:  Gregg W Stone; Judith S Hochman; David O Williams; William E Boden; T Bruce Ferguson; Robert A Harrington; David J Maron
Journal:  J Am Coll Cardiol       Date:  2015-11-23       Impact factor: 24.094

3.  Medical therapy versus percutaneous coronary intervention in ischemic heart disease: A cost-effectiveness analysis.

Authors:  Aziz Rezapour; Nader Tavakoli; Sadaf Akbar; Marjan Hajahmadi; Hosein Ameri; Reza Mohammadi; Saeed Bagheri Faradonbeh
Journal:  Med J Islam Repub Iran       Date:  2020-11-16

4.  Variations in Use of Optimal Medical Therapy in Patients With Nonobstructive Coronary Artery Disease: A Population-Based Study.

Authors:  Adam Oxner; Gabby Elbaz-Greener; Feng Qui; Shannon Masih; Nevena Zivkovic; Sami Alnasser; Asim N Cheema; Harindra C Wijeysundera
Journal:  J Am Heart Assoc       Date:  2017-11-18       Impact factor: 5.501

Review 5.  Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros.

Authors:  Konstantinos Makrilakis; Stavros Liatis
Journal:  J Diabetes Res       Date:  2017-12-14       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.